GlassScriptPhysician profile
Traci M Goldstein
NPI 1609961192
$3,582.39
in general payments reported to CMS, 2019-2025
20 companies · $916 in 2025
The $916 reported for 2025 was more than what 83% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $40.18 · 2021: $413 · 2022: $658 · 2023: $568 · 2024: $561 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $669.06 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $562.29 | 2021-2025 | Cequa, Xelpros |
| Abbvie INC. | $393.05 | 2022-2025 | |
| Alcon Vision LLC | $254.15 | 2019-2025 | Tryptyr, Eysuvis, Precision 1 |
| Tarsus Pharmaceuticals, INC. | $217.12 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $211.86 | 2019-2021 | |
| Allergan, INC. | $186.12 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $144.46 | 2019 | |
| Oyster Point Pharma, INC. | $140.32 | 2022-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $137.76 | 2024-2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $117.49 | 2022-2025 | |
| Sight Sciences, INC. | $112.97 | 2022-2023 | Tearcare System |
| Novartis Pharmaceuticals Corporation | $107.90 | 2019-2022 | |
| Dompe US, INC. | $78.13 | 2025 | Oxervate |
| Shire North American Group INC | $62.02 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $58.30 | 2021 | |
| Coopervision INC. | $46.99 | 2022-2025 | Synergeyes Contact Lens |
| Kala Pharmaceuticals, INC. | $33.75 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $24.42 | 2023 | Tobradex St |
| Leadiant Biosciences, INC. | $24.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Traci Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.